InvestorsHub Logo
icon url

Howie the Book

09/08/13 10:20 AM

#16078 RE: Mladie #16077

All the stats and info are great, thats why I'm here, a true believer...The few lucky investors in this world, saw a new product, idea, or industry developing and jumped in early and rode it to retirement. September is always a fickle month, and there are very important decisions being made all month. If this stock has to creep South a little while longer, so be it, I'll load up. I just want to see strong mgmt.,revenue, sales, favorable laws etc. and not fluff, P+D, and so called expert stock picks. If this new industry does what everybody says its going to do, PHOT and I will do just fine! See ya in the A.M.
icon url

HeedTheChief

09/08/13 1:43 PM

#16081 RE: Mladie #16077

Projection - Any Day Now!

Nobody knows.

As soon as Sterling and Company gives the green
light.

In June of this year, Grass Roots Research issued a price target of $.22 cents.

According to Cohen and his Grass Roots team, "PHOT's [GrowLife's]
business model is brilliant.
The Company has unique assets unavailable to most
micro cap stocks: access to capital, massive USA
and worldwide market demand, leveraged distribution
channels and a very strong management team.

GrowLife is actively engaged in improving and
expanding its lineup of branded products through
organic development, business alliances and acquisitions.

Based on the Company's strong performance in the
recent quarter, significant revenue growth previous
year and excellent business outlook, we believe that
GrowLife is on track to record $5.4 million in
revenues in 2013, $10.9 million in 2014 at impressive
margins.

Based on these projections and provided the Company
raises $5.0 million in capital, the Cohen Target
Price is 456.2% higher than the current price."

Based on data collected by MMJ Business Daily
from a Washington State Report, the Marijuana
Industry is expected to become a $45 billion annual
industry.

Cohen's team estimates the current size of
the medical marijuana market as $1.7 billion,
25 million potential patients, projected to grow
at 39% CAGR to $8.9
billion in 2016. The market is estimated to grow
to $29.0 billion by 2016.

It's just a waiting game now. Either way this is an
easy stock to make money, short or long.

Just my unlicensed and biased opinion, of course!
icon url

BrazenBull

09/08/13 2:08 PM

#16084 RE: Mladie #16077

Well I would just like to be at .10 seeing as how I am in here at .055 or so. Wish we could get the show on the road!